Beyrer Julie, Abedtash Hamed, Hornbuckle Kenneth, Murray James F
Department of Value, Evidence, and Outcomes (VEO) & Global Patient Safety, Eli Lilly & Company, Indianapolis, IN 46285, USA.
J Comp Eff Res. 2022 May;11(7):499-511. doi: 10.2217/cer-2022-0006. Epub 2022 Mar 17.
The credibility and value of real-world evidence (RWE) are either supported or undermined by the algorithms (i.e., operational definitions) used. We conducted a targeted evidence review of key RWE decision makers' published recommendations on RWE algorithms through April 2021. Stakeholders were regulatory bodies, other governmental agencies and payer organizations. Our review identified recommended criteria: relevance, validity, reliability, responsiveness, transparency and replicability, safety, feasibility and quality process. Stakeholders routinely recommended accuracy measures, subgroups evaluation and specific considerations for assessing exposures and covariates and the underlying real-world data (RWD) quality. The importance of stakeholder guidance on fit-for-purpose RWE algorithms is growing. We highlight gaps that future guidance and stakeholder recommendations could address.
真实世界证据(RWE)的可信度和价值会受到所使用算法(即操作定义)的支持或削弱。我们针对截至2021年4月关键RWE决策者发表的关于RWE算法的建议进行了有针对性的证据审查。利益相关者包括监管机构、其他政府机构和支付方组织。我们的审查确定了推荐标准:相关性、有效性、可靠性、响应性、透明度和可重复性、安全性、可行性和质量流程。利益相关者通常推荐准确性测量、亚组评估以及评估暴露和协变量及基础真实世界数据(RWD)质量的具体考量因素。利益相关者对适用目的的RWE算法的指导的重要性日益增加。我们强调了未来指导和利益相关者建议可以解决的差距。